Pediatric Adhd Therapeutics
1. Qelbree patent expiration
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
QELBREE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458143 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(7 years from now) | |
| US12121523 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(7 years from now) | |
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Apr, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
QELBREE family patents
